| Ghrelin, n = 10 | Placebo, n = 10 | Treatment effect (95% CI; p value†) | ||
---|---|---|---|---|---|
 | Pre-treatment | Mean D. | Pre-treatment | Mean D. |  |
| 13.3 (3.7) | 1.4 (0.8)*** | 13.4 (3.2) | 0.2 (1.3) | 1.2 (0.2 to 2.3; 0.025) |
| 640.3 (212.5) | 69.4 (45.9) | 616.8 (138.8) | 8.9 (59.7) | 60.5 (10.5 to 110.5; 0.020) |
Endurance time (s) | 389 (157) | 48 (96) | 372 (131) | 59 (60)* | -12 (-87 to 63; 0.749) |
Dyspnea (Borg) | 7.4 (1.5) | -0.5 (1.3) | 7.2 (1.6) | -0.9 (1.8) | 0.4 (-1.1 to 1.9; 0.572) |
Leg discomfort (Borg) | 5.5 (2.7) | -0.8 (1.8) | 6.3 (2.5) | -0.6 (1.7) | -0.2 (-1.9 to 1.5; 0.803) |
VT (L) | 0.97 (0.17) | 0.10 (0.08)** | 1.05 (0.12) | 0.07 (0.23) | 0.03 (-0.13 to 0.19; 0.694) |
f (breaths/min) | 34 (7) | -2 (3) | 28 (5) | -1 (6) | -1 (-5 to 4; 0.802) |
| 31.9 (6.0) | 1.5 (2.7) | 29.2 (6.4) | 0.5 (2.2) | 1.0 (-1.3 to 3.3; 0.389) |
VD/VT | 0.39 (0.06) | -0.04 (0.04)* | 0.36 (0.05) | 0.00 (0.04) | -0.04 (-0.08 to -0.00; 0.041) |
| 52.5 (12.7) | -3.7 (3.7)* | 48.0 (7.2) | 0.5 (4.2) | -4.2 (-7.9 to -0.5; 0.030) |
| 51.0 (13.6) | -3.8 (3.9)* | 45.3 (7.5) | 0.4 (4.6) | -4.1 (-8.2 to -0.1; 0.045) |
Pao2 (mmHg) | 64.4 (16.0) | -0.5 (4.2) | 66.1 (11.9) | -2.2 (5.4) | 1.7 (-2.9 to 6.2; 0.454) |
Paco2 (mmHg) | 42.7 (7.0) | -0.3 (2.3) | 42.4 (4.2) | 0.7 (3.0) | -0.9 (-3.4 to 1.6; 0.453) |
HR (beats/min) | 118 (14) | 2 (8) | 113 (13) | 7 (7)* | -6 (-13 to 2; 0.115) |
| 5.4 (1.5) | 0.5 (0.5)* | 5.5 (1.1) | -0.2 (0.5) | 0.7 (0.3 to 1.2; 0.003) |
Plasma LT (mg/dL) | 32.3 (11.8) | 3.3 (7.6) | 35.0 (14.5) | 2.5 (9.8) | 0.9 (-7.4 to 9.1; 0.824) |
Plasma NE (ng/mL) | 2.45 (1.70) | -0.08 (1.29) | 2.65 (1.80) | -0.11 (0.84) | 0.03 (-0.99 to 1.06; 0.945) |